Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation

Zhang,Ya‑Nian; Wu,Xiao‑Yang; Zhong,Ning; Deng,Jun; Zhang,Lu; Chen,Wen; Li,Xing; Zhong,Chong‑Jun

doi:10.3892/mmr.2013.1782

Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation

Authors:
- Ya‑Nian Zhang
- Xiao‑Yang Wu
- Ning Zhong
- Jun Deng
- Lu Zhang
- Wen Chen
- Xing Li
- Chong‑Jun Zhong
View Affiliations

Affiliations: Department of Thoracic Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu 215300, P.R. China, Department of Thoracic Surgery, Second Hospital Affiliated to Nantong University, Nantong, Jiangsu 216001, P.R. China
Published online on: November 7, 2013 https://doi.org/10.3892/mmr.2013.1782
Pages: 365-369

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib is an inhibitor of a number of intracellular signaling kinases with antiproliferative, anti‑angiogenic and pro‑apoptotic effects in tumor cells. Sorafenib has been used in the therapy of advanced renal cell carcinoma. In the present study, using two human non‑small cell lung cancer (NSCLC)cell lines, A549 and NCI‑H1975, the effects of sorafenib on proliferation, apoptosis and intracellular signaling were systematically characterized. The results revealed that at a low concentration (5 µM) and early time point (6 h), sorafenib is capable of significantly stimulating proliferation of A549 cells, but not NCI‑H1975 cells. In addition, the comparison of the two cell lines revealed different cell cycle redistribution and apoptotic susceptibility to sorafenib at this concentration and time point. Western blot analysis revealed that sorafenib upregulated the expression of cyclin D1 and cyclin‑dependent kinase 2 and downregulated the expression of BAX at this specific point. Furthermore, sorafenib was confirmed to regulate the expression of cyclin D1 and apoptosis‑associated proteins through the regulation of extracellular signal‑regulated kinase 1/2 phosphorylation in A549 cells. These findings suggest that, although sorafenib has the potential for use in the treatment of renal cell carcinoma, this compound may also activate NSCLC cells at a specific time point.

View Figures

View References

1	Kyle F and Spicer J: Targeted therapies in non-small cell lung cancer. Cancer Imaging. 8:199–205. 2008. View Article : Google Scholar : PubMed/NCBI
2	Ray MR, Jablons D and He B: Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med. 4:631–645. 2010. View Article : Google Scholar : PubMed/NCBI
3	Zhang X, Li Y, Li H, et al: Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis. PLoS One. 7:e401782012. View Article : Google Scholar : PubMed/NCBI
4	Larsen JE, Cascone T, Gerber DE, et al: Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J. 17:512–527. 2011. View Article : Google Scholar : PubMed/NCBI
5	Pal SK, Figlin RA and Reckamp K: Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther. 9:1931–1944. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ramakrishnan V, Timm M, Haug JL, et al: Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol. 87:277–283. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wilhelm S, Carter C, Lynch M, et al: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
8	Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
9	Jiao Y, Sun KK, Zhao L, et al: Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta Pharmacol Sin. 33:250–260. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sun KK, Zhong N, Yang Y, Zhao L and Jiao Y: Enhanced radiosensitivity of NSCLC cells by transducer of erbB2.1 (TOB1) through modulation of the MAPK/ERK pathway. Oncol Rep. 29:2385–2391. 2013.PubMed/NCBI
11	Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 28:1835–1842. 2010. View Article : Google Scholar : PubMed/NCBI
12	Bearz A, Berretta M, Lleshi A and Tirelli U: Target therapies in lung cancer. J Biomed Biotechnol. 2011:9212312011. View Article : Google Scholar : PubMed/NCBI
13	Rose A, Grandoch M, vom Dorp F, et al: Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol. 160:1690–1698. 2010. View Article : Google Scholar : PubMed/NCBI
14	Bareford MD, Park MA, Yacoub A, et al: Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res. 71:4955–4967. 2011. View Article : Google Scholar
15	Takahashi O, Komaki R, Smith PD, et al: Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res. 18:1641–1654. 2012. View Article : Google Scholar : PubMed/NCBI
16	Takezawa K, Okamoto I, Yonesaka K, et al: Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 69:6515–6521. 2009. View Article : Google Scholar : PubMed/NCBI
17	Marampon F, Gravina GL, Di Rocco A, et al: MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther. 10:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
18	Klein PJ, Schmidt CM, Wiesenauer CA, et al: The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia. 8:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
19	Shukla A, Hillegass JM, MacPherson MB, et al: ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer. 129:1075–1086. 2011. View Article : Google Scholar : PubMed/NCBI